Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

FDA Grants Copanlisib Breakthrough Designation for MZL

May 30th 2019

The FDA has granted copanlisib (Aliqopa) a breakthrough therapy designation for the treatment of adult patients with relapsed marginal zone lymphoma who have received at least 2 prior therapies.

FDA Updates Gilteritinib AML Label With OS Data

May 30th 2019

The FDA approved a supplemental new drug application to update the label for gilteritinib to include final analysis data from the phase III ADMIRAL trial, which demonstrated an improvement in overall survival with the FLT3 inhibitor compared with salvage chemotherapy in adult patients with relapsed/refractory FLT3-mutant acute myeloid leukemia.

FDA Approves Lenalidomide/Rituximab for Indolent Non-Hodgkin Lymphoma

May 28th 2019

The FDA has approved the R2 regimen of lenalidomide plus rituximab for use in patients with previously treated follicular lymphoma and marginal zone lymphoma.

OncLive Honors 15 Trailblazers With Giants of Cancer Care Program

May 28th 2019

Fifteen world-renowned leaders in hematology and oncology whose research has improved and extended the lives of millions of patients make up the 2019 class of Giants of Cancer Care® award winners.

FDA Approves Ruxolitinib for Steroid-Refractory Acute GVHD

May 24th 2019

The FDA has approved ruxolitinib for the treatment of adult and pediatric patients ≥12 years of age with steroid-refractory acute graft-versus-host disease.

FDA Panel Votes Against Quizartinib for AML

May 15th 2019

The FDA’s Oncologic Drugs Advisory Committee voted 8-3 against approving a new drug application for quizartinib for adult patients with relapsed/refractory FLT3-ITD–positive acute myeloid leukemia.

Targeted Therapies Transform Outlook of FLT3- and IDH-Mutant AML

May 8th 2019

Lyndsey Runaas, MD, discusses the newfound outlook for patients with FLT3- and IDH1/2-mutant acute myeloid leukemia given recent regulatory approvals and trial data.

Emerging Agents Spur Optimism in Myeloma

May 7th 2019

Saurabh Chhabra, MD, MS, highlights emerging agents in the field of relapsed/refractory myeloma that have oncologists optimistic for the future.

Ruxolitinib Combos Explored to Address MPN-Associated Symptoms

May 6th 2019

Laura Michaelis, MD, highlights the many ruxolitinib combinations under investigation and provided insight into the role of interferon in myeloproliferative neoplasms.

Large Myeloma Study Aims to Analyze Multiple Regimens

May 6th 2019

Therapy for patients with multiple myeloma encompasses many agents and potential combinations, but truly personalizing care will require knowing how those agents interact for maximum efficacy and incorporating patient preferences for toxicity into the care plan.

Dr. Dhakal on Early Data With BiTEs in Multiple Myeloma

May 3rd 2019

Binod Dhakal, MD, assistant professor, Medical College of Wisconsin, discusses early data with bispecific T-cell engager (BiTE) antibody constructs in multiple myeloma.

Dr. Winer Discusses the FDA Approval of Ivosidenib in AML

May 2nd 2019

Eric Stephen Winer, MD, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the FDA approval of ivosidenib in acute myeloid leukemia (AML).

FDA Approves Ivosidenib for Frontline IDH1+ AML

May 2nd 2019

The FDA has approved a supplemental new drug application for ivosidenib as a single agent for the first-line treatment of adult patients with IDH1-mutant acute myeloid leukemia, as detected by an FDA-approved test, who are ≥75 years old or are ineligible to receive intensive chemotherapy.

New Era Begins of Molecular Monitoring and Targeted Therapy in AML

May 2nd 2019

Eric S. Winer, MD, highlights the targeted therapies that have made the biggest clinical impact for patients with acute myeloid leukemia.

Venetoclax Spearheads Myriad of AML Advances

May 1st 2019

Jacqueline S. Garcia, MD, highlights key progress made in acute myeloid leukemia and remaining questions with maintenance strategies.

TKI Discontinuation Safe in CML, But Patient Selection Is Key

May 1st 2019

Although TKIs have significantly improved life expectancy for patients with chronic myeloid leukemia, investigators are actively examining ways to safely discontinue treatment without sacrificing benefit.

Dr. Bianchi on Shifting Landscape of Transplant Eligible Myeloma

April 30th 2019

Giada Bianchi, MD, physician, Dana-Farber Cancer Institute, instructor in medicine, Harvard Medical School, discusses treatment options for transplant eligible patients with multiple myeloma.

Treatment Options Expanding for Benign Hematologic Disorders

April 30th 2019

Nathan T. Connell, MD, MPH, shares key updates in the rapidly evolving treatment paradigms of benign hematologic disorders.

Dr. Nadeem on Sequencing Considerations in Multiple Myeloma

April 29th 2019

Omar Nadeem, MD, a physician at Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School, discusses sequencing challenges in multiple myeloma.

Research Propels Forward With CAR T-Cell Therapy in Pediatric ALL

April 28th 2019

Christine N. Duncan, MD, discusses the current components of CAR T-cell therapy in pediatric acute lymphoblastic leukemia.